These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33067394)

  • 1. Selective tumor antigen vaccine delivery to human CD169
    Affandi AJ; Grabowska J; Olesek K; Lopez Venegas M; Barbaria A; Rodríguez E; Mulder PPG; Pijffers HJ; Ambrosini M; Kalay H; O'Toole T; Zwart ES; Kazemier G; Nazmi K; Bikker FJ; Stöckl J; van den Eertwegh AJM; de Gruijl TD; Storm G; van Kooyk Y; den Haan JMM
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27528-27539. PubMed ID: 33067394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional CD169 on Macrophages Mediates Interaction with Dendritic Cells for CD8
    van Dinther D; Veninga H; Iborra S; Borg EGF; Hoogterp L; Olesek K; Beijer MR; Schetters STT; Kalay H; Garcia-Vallejo JJ; Franken KL; Cham LB; Lang KS; van Kooyk Y; Sancho D; Crocker PR; den Haan JMM
    Cell Rep; 2018 Feb; 22(6):1484-1495. PubMed ID: 29425504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma.
    van Dinther D; Veninga H; Revet M; Hoogterp L; Olesek K; Grabowska J; Borg EGF; Kalay H; van Kooyk Y; den Haan JMM
    Front Immunol; 2018; 9():1997. PubMed ID: 30237798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome induction of CD8
    Grabowska J; Affandi AJ; van Dinther D; Nijen Twilhaar MK; Olesek K; Hoogterp L; Ambrosini M; Heijnen DAM; Klaase L; Hidalgo A; Asano K; Crocker PR; Storm G; van Kooyk Y; den Haan JMM
    J Control Release; 2021 Mar; 331():309-320. PubMed ID: 33493613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation.
    Kawasaki N; Vela JL; Nycholat CM; Rademacher C; Khurana A; van Rooijen N; Crocker PR; Kronenberg M; Paulson JC
    Proc Natl Acad Sci U S A; 2013 May; 110(19):7826-31. PubMed ID: 23610394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD169 Defines Activated CD14
    Affandi AJ; Olesek K; Grabowska J; Nijen Twilhaar MK; Rodríguez E; Saris A; Zwart ES; Nossent EJ; Kalay H; de Kok M; Kazemier G; Stöckl J; van den Eertwegh AJM; de Gruijl TD; Garcia-Vallejo JJ; Storm G; van Kooyk Y; den Haan JMM
    Front Immunol; 2021; 12():697840. PubMed ID: 34394090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD169
    Grabowska J; Lopez-Venegas MA; Affandi AJ; den Haan JMM
    Front Immunol; 2018; 9():2472. PubMed ID: 30416504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of Liposomes for Antigen Targeting to Splenic CD169
    Nijen Twilhaar MK; Czentner L; Grabowska J; Affandi AJ; Lau CYJ; Olesek K; Kalay H; van Nostrum CF; van Kooyk Y; Storm G; Haan JMMD
    Pharmaceutics; 2020 Nov; 12(12):. PubMed ID: 33255564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD169+ Subcapsular Macrophage Role in Antigen Adjuvant Activity.
    Lisk C; Yuen R; Kuniholm J; Antos D; Reiser ML; Wetzler LM
    Front Immunol; 2021; 12():624197. PubMed ID: 33815376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelets interact with CD169
    Grabowska J; Léopold V; Olesek K; Nijen Twilhaar MK; Affandi AJ; Brouwer MC; Jongerius I; Verschoor A; van Kooten C; van Kooyk Y; Storm G; van 't Veer C; den Haan JMM
    Front Immunol; 2023; 14():1290272. PubMed ID: 38054006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Delivery of Antigen to Activated CD169
    Edgar LJ; Kawasaki N; Nycholat CM; Paulson JC
    Cell Chem Biol; 2019 Jan; 26(1):131-136.e4. PubMed ID: 30393066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8
    Grabowska J; Stolk DA; Nijen Twilhaar MK; Ambrosini M; Storm G; van der Vliet HJ; de Gruijl TD; van Kooyk Y; den Haan JMM
    Vaccines (Basel); 2021 Jan; 9(1):. PubMed ID: 33467048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ Delivery of Tumor Antigen- and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells.
    Boks MA; Bruijns SCM; Ambrosini M; Kalay H; van Bloois L; Storm G; Gruijl T; van Kooyk Y
    J Invest Dermatol; 2015 Nov; 135(11):2697-2704. PubMed ID: 26083554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.
    Klechevsky E; Flamar AL; Cao Y; Blanck JP; Liu M; O'Bar A; Agouna-Deciat O; Klucar P; Thompson-Snipes L; Zurawski S; Reiter Y; Palucka AK; Zurawski G; Banchereau J
    Blood; 2010 Sep; 116(10):1685-97. PubMed ID: 20530286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.
    Varypataki EM; van der Maaden K; Bouwstra J; Ossendorp F; Jiskoot W
    AAPS J; 2015 Jan; 17(1):216-26. PubMed ID: 25387996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of CD8⁺ T Cell Responses after Melanoma Antigen Targeting to CD169⁺ Antigen Presenting Cells in Mice and Humans.
    van Dinther D; Lopez Venegas M; Veninga H; Olesek K; Hoogterp L; Revet M; Ambrosini M; Kalay H; Stöckl J; van Kooyk Y; den Haan JMM
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30764534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
    Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
    J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted delivery of herpes simplex virus glycoprotein D to CD169
    Shen W; Wang C; Jiang J; He Y; Liang Q; Hu K
    J Control Release; 2024 Jan; 365():208-218. PubMed ID: 37981051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.